What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall for specific lots of Clobetasol Propionate Cream USP, 0.05%. This prescription-only topical medication is manufactured by Lupin Pharmaceuticals, Inc., located in Naples, Florida. While the administrative headquarters are in the United States, the physical production of this particular batch took place at Lupin Limited’s facility in Pithampur, Madhya Pradesh, India. The product is distributed nationwide across the United States, meaning it could be found in pharmacies and medical supply stores in any state, though the recall notice specifically highlights distribution patterns relevant to Florida.
The affected items are identified by their National Drug Code (NDC), which is 68180-956-04. This code corresponds to a 60-gram tube of cream packaged for retail or clinical use. It is critical to note that this recall does not apply to all Clobetasol products made by Lupin, nor does it affect every lot number ever produced. Instead, it targets two specific lots: Lot KB00427, which has an expiration date of April 30, 2028, and Lot KA00308, which expires on October 31, 2026. If you have tubes with different lot numbers or expiration dates, they are not part of this specific recall action.
The formal announcement of this recall was made on August 3, 2026. At that time, the FDA classified this as a Class II recall, which indicates a situation where use of the product may cause temporary health problems or pose a slight threat of a serious nature, but is not likely to cause serious adverse health consequences. This classification helps guide how urgently the pharmaceutical company and healthcare providers need to act to remove the defective items from shelves and patients' medicine cabinets. The scope of the distribution pattern suggests that these specific lots were widely dispersed across the U.S. market rather than being limited to a single regional pharmacy chain or hospital system.
Understanding exactly which product is involved is the first step in ensuring your safety. Clobetasol Propionate is a potent corticosteroid used to treat skin conditions such as psoriasis and eczema. Because it is a prescription drug, it is typically dispensed directly by pharmacists to patients under the care of a physician. This means that if you have been recently prescribed this medication or refilled an existing prescription, there is a possibility that your bottle may be one of the affected lots. The recall focuses on quality control failures rather than contamination or mislabeling errors in the traditional sense, but the impact on the consumer remains significant because the product may not perform as intended.
The manufacturer, Lupin Pharmaceuticals, Inc., bears responsibility for initiating this recall and coordinating with the FDA to ensure that the defective products are removed from the supply chain. The company’s Naples, Florida address serves as the point of contact for administrative purposes, while the actual manufacturing site in India is where the quality deviation occurred. Consumers do not need to worry about international shipping delays or customs issues, as the distribution pattern confirms that these items were already within the United States when the recall was triggered. The key takeaway is that only the two specific lot numbers mentioned earlier are subject to this action, and only those tubes bearing NDC 68180-956-04 should be checked immediately.
If you are unsure whether your product is affected, the most reliable method is to look at the outer packaging and the tube itself. The lot number and expiration date are typically printed clearly on the carton and the crimped end of the tube. Do not rely on memory or general purchase dates; you must verify the specific alphanumeric codes printed on your package. This precision is necessary because pharmaceutical manufacturing involves strict quality assurance protocols, and even within a single brand, different batches can have vastly different safety profiles. By focusing only on the recalled lots, you avoid unnecessary alarm for products that have passed all required testing standards.
The recall process also involves notifying healthcare providers, pharmacists, and distributors who may still have these items in stock. This is why it is important to contact your pharmacy if you have recently picked up a prescription for Clobetasol Propionate Cream. They will have the specific lot information recorded in their system and can confirm whether your particular fill was part of the affected batch. This step is crucial because it allows for immediate intervention before any potential health risks materialize. The FDA’s role in this process is to oversee the recall, ensure compliance, and communicate the details to the public to maintain transparency and trust in the drug supply chain.
In summary, the recalled product is a very specific subset of Lupin Pharmaceuticals’ Clobetasol Propionate Cream USP, 0.05%. It is defined by its NDC 68180-956-04, its two lot numbers (KB00427 and KA00308), and its expiration dates of April 30, 2028, and October 31, 2026, respectively. The recall was announced on August 3, 2026, and applies to products distributed nationwide in the United States. By identifying these exact details, you can determine whether your medication is part of this recall and take appropriate next steps to ensure your health and safety.
The hazard, explained
At first glance, a tube of prescription cream might seem like a straightforward medical product. You apply it to your skin to treat inflammation, itching, or rashes, and you expect the medication inside to work exactly as prescribed. However, in this specific recall involving Lupin Pharmaceuticals’ Clobetasol Propionate Cream USP, 0.05%, the core issue lies in something invisible to the naked eye: content uniformity. This term refers to how evenly the active drug ingredient is distributed throughout the entire batch of cream. When a pharmaceutical manufacturer says a product has "failed content uniformity specifications," it means the mixing process did not create a consistent blend. Instead of every gram of cream containing the precise amount of Clobetasol Propionate intended by the formula, the concentration varies unpredictably from spot to spot.
Physically, this happens during the manufacturing phase when the active pharmaceutical ingredient is combined with the base cream components. If the mixing equipment malfunctions, the timing is off, or the ingredients are not integrated thoroughly enough, you end up with a product that is chemically unstable in terms of dosage distribution. In some parts of the tube, the concentration of the drug may be significantly lower than 0.05%. In other parts, it may be dangerously higher. This inconsistency means that two applications of what looks and feels like the exact same amount of cream could deliver vastly different doses to your body.
This variability creates a dual risk for patients relying on this medication. On one hand, if you happen to draw cream from a section with lower drug concentration, you may receive a sub-therapeutic dose. For a potent steroid like Clobetasol Propionate, which is used to treat stubborn skin conditions, an insufficient dose means your condition will not improve. You might continue to suffer from severe itching, redness, or swelling, potentially leading to further skin damage or secondary infections because the underlying inflammation was never properly controlled.
On the other hand, and perhaps more immediately concerning, is the risk of overdose. If you apply cream from a section with higher-than-specified drug concentration, your skin absorbs more Clobetasol Propionate than intended. Because this is a high-potency topical corticosteroid, excessive absorption can lead to serious systemic side effects. These can include thinning of the skin (atrophy), stretch marks, changes in skin color, and potentially adrenal suppression, where your body’s natural hormone production is disrupted. For patients with sensitive skin or those using the medication over large areas, this inconsistency transforms a standard treatment into an unpredictable health hazard.
It is important to understand that you cannot detect this problem through sensory inspection. The cream will look smooth, white or off-white, and have the expected consistency. It will smell like the usual product. There are no visible clumps, discolorations, or separations that signal a content uniformity failure. This is why regulatory agencies like the FDA issue recalls for these types of defects: the danger is hidden in the chemistry, not the appearance. Without checking the lot number against an official recall list, there is no way for a consumer to know if their specific tube contains a safe, consistent dose or a potentially harmful variation.
In summary, the hazard here is not that the drug is wrong, but that its reliability is compromised. Clobetasol Propionate is a powerful medication that requires precise dosing to be both effective and safe. When content uniformity fails, that precision is lost, leaving patients vulnerable to either ineffective treatment or unintended adverse effects from unpredictable drug exposure.
Who is most at risk
When we talk about who is "most at risk" in a pharmaceutical recall like this one, it is important to distinguish between two different types of danger. First, there is the immediate physical risk to patients who use the specific product and find that its strength is inconsistent. Second, there is the logistical and clinical risk faced by people who rely on this medication for chronic conditions and may suddenly lose access to their prescribed treatment. In the case of Lupin Pharmaceuticals’ recall of Clobetasol Propionate Cream USP 0.05%, both groups are affected, but in distinct ways.
The primary group at risk here is anyone currently using this prescription cream to treat inflammatory skin conditions such as severe eczema, psoriasis, or dermatitis. Clobetasol is a high-potency corticosteroid, which means it is a strong medication typically reserved for short-term use on thick, resistant patches of skin. Because the FDA has identified that this specific batch failed content uniformity specifications, the amount of active drug in each tube may be unpredictable. For some users, the cream might contain too little medication, leading to a flare-up of their condition because the treatment is ineffective. For others, it might contain too much, potentially increasing the risk of local side effects like skin thinning, stretching, or discoloration, especially if applied over large areas or for longer than prescribed. While the recall notice does not cite specific injuries yet, the unpredictability itself is the hazard.
Certain populations are generally more vulnerable to fluctuations in topical steroid potency. Elderly patients often have thinner skin and reduced ability to absorb nutrients, making them more susceptible to systemic absorption of steroids or local tissue damage if the concentration is higher than expected. Similarly, individuals with compromised skin barriers—such as those with widespread open lesions or very sensitive skin types—may react more severely to inconsistent dosing. Children are also a sensitive group when it comes to potent steroids, as their body surface area to weight ratio is higher, which can lead to greater systemic exposure if the drug potency is erratic.
Beyond direct physical effects, there is a significant risk for patients who have few alternatives. Clobetasol is often prescribed when milder steroids have failed. If you are in this group and your supply is recalled, you face the risk of untreated inflammation, which can lead to secondary infections, severe discomfort, and sleep disruption. The stress of navigating a replacement prescription while dealing with an active skin condition can be overwhelming. It is crucial to remember that while the product is defective, the underlying condition remains serious. Therefore, the "risk" extends beyond the cream itself to the gap in care that may occur while you wait for a remedy or a different brand. If you are part of any of these groups, do not stop using your medication abruptly without consulting your doctor, as this can sometimes cause a rebound effect in skin conditions. Instead, contact your healthcare provider immediately to discuss safe alternatives.
How to tell if you have the recalled item
When a pharmaceutical recall is announced, the most immediate and often difficult step is confirming whether the specific tube sitting in your medicine cabinet matches the official alert. Because Clobetasol Propionate Cream is a prescription medication, it is not typically sold on open shelves with bright retail packaging that makes identification easy. Instead, you must rely on the precise labeling details printed directly on the product container. The recall issued by the FDA involves Lupin Pharmaceuticals Inc., so your first step is to examine the outer carton and the tube itself for the manufacturer’s name. You are looking specifically for "Lupin Pharmaceuticals" listed as the entity for whom the drug was manufactured, often accompanied by the address in Naples, Florida.
The most critical piece of information you need to verify is the National Drug Code (NDC), which serves as a unique three-segment identifier for every marketed drug product. For this specific recall, the targeted NDC is 68180-956-04. This code should be printed clearly on the box and/or the tube. If your product does not have this exact NDC, it is not part of this particular recall action, even if it is the same strength or manufacturer. Alongside the NDC, you must check the lot number (also known as the lot code or batch number), as recalls are almost always limited to specific production runs. The FDA notice identifies two specific lots involved in this distribution: KB00427 and KA00308. Locate these alphanumeric codes, usually printed near the expiration date or along the crimped edge of the tube.
In addition to the codes, verify the physical specifications of the product to ensure a complete match. The recalled item is Clobetasol Propionate Cream USP at a strength of 0.05%. It is important to confirm that you have the cream formulation and not an ointment or gel, as these are different drug products. Furthermore, check the size of the container; this recall applies specifically to the 60 g tube. Do not assume that all Lupin-manufactured Clobetasol is affected, as other lot numbers or package sizes may be safe. Finally, look at the expiration date printed on the label. The recalled lots have expiration dates of April 30, 2028 (for lot KB00427) and October 31, 2026 (for lot KA00308). If your tube has a different expiration date or lot number, it is not included in this recall. Take the time to cross-reference every one of these details—NDC, lot number, strength, size, and manufacturer—before taking any action.
What to do — step by step
If you have been prescribed Clobetasol Propionate Cream USP, 0.05%, specifically in the 60-gram tubes manufactured by Lupin Pharmaceuticals, your immediate priority is to ensure that this medication does not enter your treatment routine. The FDA has classified this recall as a Class II event, which indicates that use of the product may cause temporary health problems or pose a slight threat of a serious nature. Because the specific remedy for this recall has not been publicly stated in the official FDA report, you cannot assume there is a standard return-to-store process or an automatic mail-in refund available right now. This absence of a specified remedy means that your next actions must be driven by caution and direct communication rather than following a pre-packaged instruction sheet.
Your first concrete step is to stop using the cream immediately if you have not yet started, or discontinue it if you are currently in the middle of a course. Clobetasol is a high-potency corticosteroid used to treat skin conditions like psoriasis and eczema. The hazard here is that the product failed content uniformity specifications. In plain terms, this means the amount of active drug in the cream is not consistent throughout the tube. One part of the tube might have too much medication, while another part has too little. Using a product with inconsistent dosing can lead to ineffective treatment or unexpected side effects because you cannot know exactly how much steroid your skin is absorbing at any given moment. Do not try to save it for later or share it with family members.
The second step is to physically identify the specific items in your possession. Look closely at your tube for the National Drug Code (NDC) 68180-956-04. More importantly, check the lot numbers printed on the packaging. This recall affects two specific lots: KB00427 and KA00308. Even if you have other tubes from Lupin Pharmaceuticals, they are not part of this recall unless they match these exact lot numbers. If you have discarded the box but still have the tube, look for the lot number printed directly on the crimped end or the body of the tube. If you cannot verify the lot number, it is safest to treat any Lupin-manufactured Clobetasol from this period with extreme caution until you can confirm its identity.
The third step involves contacting your healthcare provider. Since a specific remedy like a refund or replacement program is not stated in the recall notice, your doctor or dermatologist is your most reliable source for guidance on how to proceed. They need to know that you possess potentially non-compliant medication so they can adjust your treatment plan if necessary. They may prescribe a different brand of Clobetasol Propionate or an alternative medication entirely to ensure your skin condition continues to be managed effectively and safely. Do not wait for your next scheduled appointment; call their office now to inform them of the recall.
Your fourth step is to contact the manufacturer or distributor directly, as they will have the most accurate information regarding how to dispose of or return the product. The recall notice identifies Lupin Pharmaceuticals, Inc. in Naples, FL, as the entity for whom the drug was manufactured, and Lupin Limited in India as the actual manufacturer. You should seek out their official customer service or pharmaceutical safety contact channels. Ask them explicitly: "There is no stated remedy in the FDA report. What are your current instructions for patients who have this lot?" They may provide a prepaid shipping label, direct you to a local pharmacy for disposal, or give specific instructions on how to destroy the product safely at home. Do not throw the medication in the household trash until you have confirmed this is safe and permitted, as improper disposal can be an environmental hazard.
Finally, monitor your health. If you have already used some of this cream, pay close attention to your skin’s response. Because the content uniformity was compromised, you might experience a lack of therapeutic effect if the dose was too low, or increased irritation and skin thinning if the dose was too high. Report any unusual reactions, such as severe redness, burning, or failure of your skin condition to improve, to your doctor immediately. While Class II recalls are generally not life-threatening, ignoring inconsistent medication can lead to prolonged suffering from the underlying skin condition or unnecessary adverse effects from the steroid. Stay calm, verify your lot numbers, and let your healthcare provider guide your next medical decisions.
Your refund, repair, or replacement options
When you encounter a product recall, the immediate concern is often what happens to your money and how you replace the item you purchased. In this specific case involving Lupin Pharmaceuticals Inc., the situation regarding financial restitution is defined by a significant gap in the public record. The official FDA recall notice for Clobetasol Propionate Cream USP, 0.05%, does not explicitly state whether Lupin Pharmaceuticals intends to issue refunds, provide credit memos, or offer a direct replacement product. This absence of stated remedy details is not uncommon in Class II drug recalls, which often prioritize the physical removal of potentially non-compliant inventory from the supply chain over immediate consumer financial transactions. It is crucial to understand that "no stated remedy" in the recall notice does not necessarily mean you are left without recourse; it simply means you must take the next step to discover your specific options.
Because the recall was initiated due to a failure in content uniformity specifications, the primary action required is the return of the product. You should contact the pharmacy where you originally filled your prescription or the healthcare provider who prescribed the medication. Pharmacies are typically the first point of contact for drug recalls because they manage the inventory and have established relationships with the manufacturer’s wholesale distributors. When you reach out to them, explain that you possess one of the affected lots: either Lot KB00427 (expiring 4/30/2028) or Lot KA00308 (expiring 10/31/2026). They will guide you on how to return the tube, whether through a mail-back program, a drop-off at their store, or by having a courier collect it. This step is vital for ensuring the product does not remain in your home or get inadvertently dispensed to another patient.
Regarding financial compensation, your options depend largely on the policies of the dispensing pharmacy and the insurance carrier that covered the cost. If you paid out-of-pocket, ask the pharmacy about their specific return policy for recalled items. Many pharmacies will process a full refund or store credit once they confirm the product is part of the recall lot, even if the FDA notice does not list this as a mandatory requirement. If you used insurance, the pharmacy may handle the reimbursement directly with your insurer, resulting in a corrected claim and no out-of-pocket cost to you. Do not assume you must pay for a replacement prescription; reputable pharmacies and manufacturers generally absorb the cost of recalled pharmaceuticals to maintain patient safety and trust.
If you are unable to reach the original pharmacy or if they cannot assist with the financial aspect, you may need to contact Lupin Pharmaceuticals Inc. directly. While the recall notice does not provide a specific consumer hotline for refunds, Lupin Limited in India and Lupin Pharmaceuticals Inc. in Naples, FL, are the responsible entities. You can attempt to reach their corporate customer service or quality assurance departments through their official website or general business contacts found in public regulatory databases. When contacting them, have your lot number and expiration date ready. Be clear that you are seeking instructions for the return of a Class II recalled product and inquiring about any available reimbursement options. Keep records of all communications, as this documentation may be necessary if you need to dispute charges with your credit card company or insurance provider later.
In summary, while the recall notice does not lay out a clear path for refunds or replacements, the standard practice in pharmaceutical recalls is that the patient should not bear the financial burden of a manufacturer’s quality control failure. Your most effective immediate action is to stop using the cream and contact your pharmacy. They are equipped to handle the logistical return of the drug and can often facilitate the financial resolution more smoothly than an individual consumer attempting to navigate manufacturer contacts alone. Always prioritize stopping use immediately, as the content uniformity issue means you may not be getting the correct dose of this potent corticosteroid.
What can happen if you ignore it
When a pharmaceutical product fails to meet its established quality specifications, the immediate concern might seem technical and abstract. However, ignoring a recall notice for Clobetasol Propionate Cream USP is not a matter of simple inconvenience; it introduces a tangible and unpredictable risk to your physical health. The specific issue identified in this recall involves failed content uniformity specifications. While this term sounds like a standard manufacturing metric, its real-world implication is that the medication you are applying may not contain the amount of active ingredient printed on the label. This discrepancy can manifest in two dangerous directions: the cream may contain too little of the drug, or it may contain too much.
If the content uniformity failure results in a lower-than-stated concentration of Clobetasol Propionate, you are effectively using an under-dosed medication. You might apply the cream for days or weeks, believing you are treating your skin condition—such as severe inflammation, itching, or rashes—while receiving little to no therapeutic benefit. This delay in effective treatment allows the underlying skin condition to worsen, potentially leading to secondary infections, increased discomfort, and the need for more aggressive medical interventions later. In this scenario, ignoring the recall costs you time and health outcomes without providing any safety gain.
Conversely, and perhaps more immediately hazardous, is the risk of receiving a dose that is too high. Clobetasol Propionate is a potent corticosteroid designed for specific, controlled use. If a particular tube from the affected lots contains significantly more of the active drug than intended, you are inadvertently exposing your skin to a higher systemic load of steroids. Potent topical corticosteroids can cause serious side effects when used in excess, including thinning of the skin (atrophy), stretch marks, changes in skin color, and increased susceptibility to infections. In rare cases, excessive absorption of potent steroids can lead to systemic effects that interfere with your body’s natural hormone production.
Because this recall involves products distributed nationwide, the variability in content uniformity means you cannot predict which direction the error leans without laboratory testing. Continuing to use the cream from Lot# KB00427 or KA00308 means gambling with your health by accepting an uncontrolled variable in your treatment plan. There are no reported injuries listed in the current FDA data for this specific recall, but the potential for harm exists precisely because the dosage is unreliable. You cannot know if you are getting a safe dose or a dangerous one until the product is removed from your routine. Ignoring the notice leaves you in the dark about these risks, potentially leading to prolonged exposure to an unpredictable chemical concentration that your body may not be prepared to handle safely.
Staying safe: broader tips
While this specific recall involves a pharmaceutical product manufactured by Lupin Pharmaceuticals, the underlying principle of quality control in medication is universal. When you use prescription topical creams like Clobetasol Propionate, you are relying on precise chemical engineering to ensure safety and efficacy. Because these products are often used for serious skin conditions, it is vital to understand that "natural" or "generic" does not mean less rigorous. In fact, generic drugs must meet the same strict FDA standards as brand-name equivalents regarding dosage, strength, and purity. The hazard here—failed content uniformity—means that individual doses might contain too much or too little of the active ingredient. This is why paying attention to regulatory alerts is not just about avoiding a bad batch; it is about understanding how the pharmaceutical supply chain works and where potential gaps can occur.
To stay safe with any medication, start by building a routine of verification. Keep a dedicated folder, either digital or physical, for all your prescription information, including NDC (National Drug Code) numbers, lot numbers, and expiration dates. When you receive new medication, take a moment to compare the label against your pharmacy’s record. If anything looks off—such as unusual packaging, discoloration, or an unexpected smell—do not use it. Contact your pharmacist immediately. They are the most accessible safety experts you have and can verify if your specific bottle is part of a broader distribution pattern before any public recall even begins.
Furthermore, consider how you store your medications. Many topical creams and ointments are sensitive to temperature fluctuations and humidity, which can degrade the active ingredients over time, potentially leading to inconsistent potency even in non-recalled products. Store them in a cool, dry place away from direct sunlight, unless the label specifically instructs otherwise. Avoid storing them in bathrooms where steam and heat vary wildly. Proper storage preserves the integrity of the drug matrix, ensuring that when you apply it, you are getting exactly what the manufacturer intended.
Finally, make recall monitoring a habitual part of your health management. Sign up for email alerts from the FDA’s MedWatch program and subscribe to updates from your local pharmacist. These notifications often provide detailed information on distribution patterns, helping you determine if your specific pharmacy received affected lots. By staying informed and proactive, you transform passive consumption into active health management, ensuring that every dose you take is both safe and effective.